List of Excipients in Branded Drug GLIMEPIRIDE

« Back to Dashboard

Generic Drugs Containing GLIMEPIRIDE

Company	Ingredient	NDC	Excipient
Liberty Pharmaceuticals Inc	glimepiride	0440-6564	CELLULOSE, MICROCRYSTALLINE
Liberty Pharmaceuticals Inc	glimepiride	0440-6564	LACTOSE MONOHYDRATE
Liberty Pharmaceuticals Inc	glimepiride	0440-6564	MAGNESIUM STEARATE
Liberty Pharmaceuticals Inc	glimepiride	0440-6564	POLOXAMER 188
Liberty Pharmaceuticals Inc	glimepiride	0440-6564	POVIDONE K30

What are the Most Frequently-Used Excipients in GLIMEPIRIDE?

# Of NDCs	Excipient
1	ALUMINUM OXIDE
112	CELLULOSE, MICROCRYSTALLINE
2	CI 77492
1	CROSPOVIDONE
25	D&C YELLOW NO. 10

Glimepiride Excipient Strategy and Commercial Opportunities

Last updated: October 21, 2026

Glimepiride is a low-dose, immediate-release sulfonylurea with established generic competition and limited reference-product exclusivity. The strongest commercial opportunities are not basic tablet manufacture, but improved dissolution, robust low-dose content uniformity, fixed-dose combinations, patient-friendly dosage forms, and cost-efficient manufacturing for emerging markets. Excipient selection must address glimepiride’s low aqueous solubility, dose uniformity at 1-4 mg strengths, and the need to maintain rapid oral release.

What is the regulatory and commercial status of glimepiride?

Glimepiride is an oral antidiabetic drug used with diet and exercise to improve glycemic control in adults with type 2 diabetes. The U.S. reference product, Amaryl, was approved by the FDA in 1995. Commercial tablets are generally supplied in 1 mg, 2 mg, 4 mg, and 8 mg strengths, although availability varies by market.[1]

Attribute	Glimepiride profile
Therapeutic class	Second-generation sulfonylurea
Mechanism	Stimulates pancreatic insulin secretion through ATP-sensitive potassium-channel modulation
Dosage form	Immediate-release oral tablet
Common strengths	1 mg, 2 mg, 4 mg, 8 mg
Typical starting dose	1 mg once daily
Maximum labeled dose	8 mg once daily in the U.S. label
Biopharmaceutics issue	Low aqueous solubility and dissolution sensitivity
Reference product	Amaryl
Regulatory pathway for competitors	Abbreviated New Drug Application for generics
Biosimilar pathway	Not applicable
Primary commercial competition	Generic tablets and fixed-dose combinations

Glimepiride is a small molecule, not a biologic. Biosimilar competition therefore does not apply. Competitive products generally rely on abbreviated regulatory pathways supported by pharmaceutical equivalence and bioequivalence rather than clinical development comparable to the reference product.[2]

What excipients are used in glimepiride tablets?

Marketed glimepiride tablets commonly use standard immediate-release excipients. The precise composition differs by manufacturer and strength.

Excipient category	Common examples	Primary function
Diluent	Lactose monohydrate, microcrystalline cellulose, dibasic calcium phosphate	Provides tablet mass and improves compressibility
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Sodium starch glycolate, crospovidone, croscarmellose sodium	Promotes tablet breakup
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces sticking and ejection force
Glidant	Colloidal silicon dioxide	Improves powder flow
Surfactant	Sodium lauryl sulfate or polysorbate-type systems	Improves wetting and dissolution
Film former	Hypromellose, polyvinyl alcohol	Provides protection, color, and identification
Colorant	Iron oxides, aluminum lakes, approved dyes	Supports strength differentiation and branding

The Amaryl label identifies conventional tablet excipients, including lactose monohydrate, sodium starch glycolate, povidone, microcrystalline cellulose, and magnesium stearate, with colorants varying by strength.[1] Generic manufacturers can use different excipients if the finished product meets applicable quality and bioequivalence requirements.

Why does the low dose create formulation risk?

A 1 mg glimepiride tablet can contain less than 1% active pharmaceutical ingredient by weight. Small segregation or blending errors can produce meaningful potency variation. The formulation therefore requires:

• Controlled particle-size distribution.
• Reliable drug dilution.
• Low-segregation powder handling.
• Validated blend uniformity.
• Tight control of lubricant concentration and mixing time.
• Robust assay and content-uniformity testing.

Direct compression can reduce manufacturing cost, but it places greater demands on powder flow, compressibility, and segregation control. Wet granulation can improve content uniformity and compressibility but adds processing time, moisture exposure, drying requirements, and scale-up complexity.

Which excipient strategy is best for glimepiride?

The preferred strategy depends on the commercial objective. A low-cost generic tablet should use a conventional, regulatory-familiar formula. A differentiated product should use excipients or processing technologies that improve dissolution, dose flexibility, adherence, or manufacturing performance.

Commercial objective	Preferred formulation approach	Commercial rationale
Lowest-cost generic	Direct compression or simple wet granulation	Minimizes process complexity
Improved dissolution	Surfactant-assisted formulation, micronization, or solid dispersion	Addresses low aqueous solubility
Robust low-dose uniformity	Wet granulation or ordered mixing with a high-functionality filler	Reduces segregation risk
Pediatric or geriatric use	Orally disintegrating tablet or granule formulation	Improves administration convenience
Combination therapy	Co-formulated glimepiride-metformin tablet	Reduces pill burden
Premium branded generic	Modified-release or patient-friendly delivery system	Creates differentiation, subject to regulatory and clinical requirements
Manufacturing transfer	Spray-dried or co-processed excipient platform	Improves scale-up consistency

For a standard immediate-release product, the most defensible formulation is usually a lactose or microcrystalline-cellulose-based matrix with a superdisintegrant and a low concentration of lubricant. Sodium starch glycolate, crospovidone, and croscarmellose sodium can each support rapid disintegration, but their performance depends on compression force, particle size, porosity, and formulation moisture.

How can excipients improve glimepiride dissolution?

Glimepiride has limited aqueous solubility. Dissolution can become a critical quality attribute, particularly when formulation changes alter wetting, particle size, tablet porosity, or disintegration time.[3]

Surfactant-based systems

A small amount of a wetting agent can improve contact between glimepiride particles and gastrointestinal fluid. Sodium lauryl sulfate is a practical option for conventional tablets, but excessive levels can affect tablet strength, dissolution profiles, gastrointestinal tolerability, and analytical comparability.

Surfactants are most useful when the underlying problem is poor wetting. They are less effective when dissolution is limited primarily by crystal lattice energy or particle agglomeration.

Micronized drug and ordered mixing

Micronization increases surface area and can accelerate dissolution. It also increases electrostatic charging, cohesion, dust generation, and segregation risk. Ordered mixing, in which fine glimepiride particles adhere to larger carrier particles, can improve blend uniformity when carefully controlled.

The commercial benefit is strongest where the manufacturer can demonstrate a reproducible dissolution advantage without introducing a complex new dosage form.

Solid dispersions

Polyvinylpyrrolidone, hypromellose, hydroxypropyl methylcellulose acetate succinate, and related polymers can support amorphous solid-dispersion approaches. These systems may improve apparent solubility, but they introduce risks involving recrystallization, hygroscopicity, residual solvent, thermal processing, and long-term stability.

Solid dispersion technology is more commercially attractive for a differentiated product than for a commodity generic because development and manufacturing costs are higher.

Lipid and liquisolid systems

Lipid-based excipients, nonvolatile solvents, and liquisolid carriers can improve wetting and dissolution. They may require specialized processing and tighter control of moisture, migration, content uniformity, and tablet hardness. Their use is most compelling when a company seeks an intellectual-property position around a formulation platform.

What formulations are protected or commercially differentiable?

A conventional glimepiride tablet is difficult to differentiate through composition alone because the active ingredient is established and the dosage form is simple. Commercially meaningful differentiation is more likely in the following areas:

1. Orally disintegrating tablets.
2. Taste-masked granules or mini-tablets.
3. Fixed-dose combinations with metformin.
4. Extended-release or pulsatile-release systems.
5. Amorphous or nanostructured glimepiride formulations.
6. Unit-dose sachets or dispersible tablets.
7. Low-cost, heat- and humidity-resistant formulations for tropical markets.
8. Manufacturing processes that improve content uniformity at 1 mg strength.

A formulation patent must provide more than a substitution of one conventional excipient for another. Stronger claims typically depend on a defined dissolution profile, particle-size range, solid-state form, excipient ratio, process condition, or clinical performance.

How does glimepiride compare with competing diabetes drugs?

Glimepiride competes with other sulfonylureas, metformin, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, and insulin products. Its principal commercial advantages are low unit cost, oral administration, long market history, and broad generic manufacturing capability. Its principal disadvantages include hypoglycemia risk and weight gain, which limit its strategic position against newer drug classes.[4]

Drug or class	Formulation opportunity	Cost position	Main commercial pressure on glimepiride
Metformin	Immediate-release, extended-release, fixed-dose combinations	Low	First-line use and broad availability
Gliclazide	Modified-release tablets	Low to moderate	Alternative sulfonylurea positioning
Glibenclamide	Conventional tablets	Low	Older low-cost alternative
DPP-4 inhibitors	Conventional tablets and combinations	Moderate to high	Lower hypoglycemia concern
SGLT2 inhibitors	Conventional tablets	High relative to generics	Cardiovascular and renal outcome advantages
GLP-1 receptor agonists	Injectable and oral specialty products	High	Weight-loss and outcome-driven prescribing
Insulin	Injectable or device-based	Variable	Greater glucose-lowering intensity

The strongest residual market for glimepiride is price-sensitive care, combination therapy, and regions where newer therapies remain less accessible.

What fixed-dose combinations offer the largest opportunity?

Glimepiride-metformin combinations are the most commercially established combination opportunity. They reduce pill burden and target patients already receiving both agents. Development challenges include:

• Different dose ratios.
• Metformin’s high dose relative to glimepiride.
• Tablet size and swallowability.
• Moisture sensitivity and manufacturing segregation.
• Separate dissolution requirements for both actives.
• Dose titration limitations.

Possible combinations include glimepiride with metformin immediate release or extended release. A manufacturer may differentiate through multiple strengths, scored tablets, moisture-protective packaging, or a bi-layer design that separates incompatible processing conditions.

Other combinations, including glimepiride with pioglitazone, have commercial precedent in some markets but face greater competitive pressure from newer therapies. The regulatory and patent position must be evaluated separately for each jurisdiction and product configuration.

What manufacturing and intellectual-property barriers exist?

Glimepiride has a mature small-molecule supply chain. The core compound is not protected by biologic manufacturing complexity. Manufacturing barriers are therefore operational rather than fundamental.

Key barriers include:

• Reliable supply of pharmaceutical-grade glimepiride.
• Control of polymorphic or particle-size variation.
• Uniform distribution at low dose.
• Consistent dissolution across strengths.
• Scale-up of granulation and drying.
• Control of lubricant sensitivity.
• Stability under heat and humidity.
• Bioequivalence after excipient or process changes.

Formulation patents may be available for novel solid forms, particle-engineered products, combinations, modified-release systems, and manufacturing processes. However, a broad commercial strategy should not assume that an excipient combination alone creates durable exclusivity. Patent strength generally improves when the claims are tied to measurable technical results and a narrow but reproducible formulation window.

What is the Orange Book and Paragraph IV status of glimepiride?

The Orange Book lists FDA-approved prescription drug products and related patent and exclusivity information. Glimepiride is subject to generic competition through the ANDA pathway, and the original reference-product exclusivity period has expired.[2]

Paragraph IV litigation is most relevant when an ANDA applicant challenges an unexpired listed patent. For a mature product such as glimepiride, current commercial risk is usually driven by generic price competition, manufacturing capacity, and formulation differentiation rather than reference-product patent blocking.

Any current Orange Book patent listing, Paragraph IV certification, or litigation position must be assessed against the FDA’s live listing and applicable court records because listings and litigation can change by product, strength, and formulation.[2,5]

What patent litigation and settlement risks affect glimepiride?

The primary litigation risks are likely to arise from:

• Formulation patents covering enhanced dissolution.
• Combination-product patents.
• Modified-release claims.
• Solid-state or particle-size claims.
• Process patents involving granulation or drying.
• Trademark and trade-dress disputes involving tablet appearance.

Biosimilar litigation is not relevant because glimepiride is not a biologic. For a conventional generic tablet, the higher-probability disputes concern ANDA certifications, formulation patents, manufacturing confidentiality, and regulatory exclusivity for a newly developed combination or delivery system.

Settlement economics are likely to be limited for an old, low-priced molecule unless the challenged product has a differentiated formulation, strong market share, or a combination product with separate commercial value.

When does glimepiride lose exclusivity and what does that mean commercially?

Glimepiride’s original U.S. market exclusivity and core compound patent protection have expired, allowing multiple generic manufacturers to compete. The reference product therefore has limited ability to command a premium based solely on the active ingredient.

Commercial value can still be created through:

• Regional registrations.
• Reliable supply.
• Lower-cost manufacturing.
• Combination products.
• Patient-friendly dosage forms.
• Contract manufacturing.
• Private-label supply.
• Formulation or process licensing.
• Distribution in markets with lower generic penetration.

The revenue opportunity is volume-driven. A low-cost formulation with reliable quality and broad regulatory registrations is generally more attractive than an expensive delivery platform without a clear reimbursement or adherence benefit.

Which companies and business models are positioned to compete?

The competitive landscape includes originator-linked products, multinational generic companies, regional manufacturers, contract development and manufacturing organizations, and branded-generic distributors.

Business model	Best opportunity
Large generic manufacturer	Multi-country registration and low-cost supply
Regional pharmaceutical company	Fixed-dose combinations and local distribution
CDMO	Formulation development, scale-up, and technology transfer
Specialty drug company	Orally disintegrating or modified-release product
Public-sector supplier	High-volume procurement and stable supply
Licensing company	Patented dissolution, solid-state, or combination technology

A formulation owner can license a glimepiride platform to regional manufacturers where local registration, pharmacopoeial compliance, and supply-chain access matter more than global brand recognition.

What is the strongest commercial excipient strategy?

The strongest near-term strategy is a robust immediate-release tablet using familiar excipients, with dissolution and content uniformity optimized through particle engineering and controlled granulation. The strongest differentiated strategy is a glimepiride-metformin product or patient-friendly dosage form supported by a clear clinical or adherence benefit.

A practical development sequence is:

1. Establish a conventional reference-like formulation.
2. Characterize particle size, solid state, flow, blend uniformity, disintegration, and dissolution.
3. Compare direct compression with wet granulation.
4. Screen one superdisintegrant and one wetting strategy.
5. Confirm bioequivalence risk before introducing advanced solubility technology.
6. Develop combination strengths only after single-entity manufacturing is robust.
7. Protect measurable formulation or process improvements with targeted patent claims.

Key Takeaways

• Glimepiride is a mature, genericized small molecule with limited value from active-ingredient exclusivity.
• Excipient strategy should prioritize low-dose content uniformity, rapid dissolution, tablet robustness, and manufacturing cost.
• Lactose, microcrystalline cellulose, povidone, sodium starch glycolate, crospovidone, croscarmellose sodium, and magnesium stearate are commercially practical excipient choices.
• Surfactants, micronization, solid dispersions, and lipid systems can improve dissolution but increase development and manufacturing complexity.
• Glimepiride-metformin fixed-dose combinations offer the clearest commercial opportunity.
• Biosimilar risk does not apply.
• Current value is concentrated in generic supply, regional registrations, combination products, and differentiated dosage forms.
• Formulation patents are stronger when tied to defined technical results rather than routine excipient substitution.
• The primary competitive risks are price erosion, newer diabetes therapies, manufacturing failures, and limited differentiation.

FAQs About Glimepiride Excipient and Commercial Strategy

Can glimepiride be formulated as an orally disintegrating tablet?

Yes. An orally disintegrating tablet can improve administration for patients with swallowing difficulty. The formulation must control taste, friability, disintegration time, moisture uptake, and dose uniformity.

Which excipient is best for glimepiride dissolution?

No single excipient is universally superior. Crospovidone or sodium starch glycolate can improve disintegration, while a controlled amount of surfactant can improve wetting. The optimal choice depends on particle size, compression force, tablet porosity, and the target dissolution profile.

Is glimepiride suitable for a sustained-release formulation?

Yes, technically. A sustained-release product could reduce dosing frequency, but it would require a new formulation, pharmacokinetic assessment, and likely clinical or bioequivalence development. The commercial case is weaker because glimepiride is already administered once daily.

What is the main stability risk for glimepiride tablets?

The main risks are moisture exposure, changes in dissolution, powder segregation, and physical instability caused by particle-size or solid-state variation. Packaging selection is important for products distributed in hot and humid markets.

Can a glimepiride excipient combination support a new patent?

It can if the combination produces a novel and reproducible technical result, such as a defined dissolution profile, improved stability, reduced variability, or a clinically relevant delivery benefit. Routine substitution of one conventional filler or disintegrant for another is less likely to support strong, durable claims.

References

1. U.S. Food and Drug Administration. (1995). Amaryl (glimepiride) prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. DailyMed. (2024). Glimepiride tablet prescribing information. National Library of Medicine.
4. American Diabetes Association Professional Practice Committee. (2024). Pharmacologic approaches to glycemic treatment: Standards of care in diabetes. Diabetes Care, 47(Supplement 1).
5. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database.